Bromday Twinpack (bromfenac sodium)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Bromfenac sodium is a prototypical nonsteroidal anti-inflammatory agent (NSAIA).
Bromfenac sodium is a prototypical NSAIA. The drug inhibits the synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase (COX), including both COX-1 and COX-2 isoenzymes. The mechanism(s) of the ocular effects of NSAIAs appears to be associated principally with the inhibition of ocular prostaglandin synthesis.
By reducing ocular production of prostaglandins, NSAIAs can inhibit ocular inflammation and other reactions mediated primarily or secondarily by prostaglandins.
USES: This medication is used to treat swelling (inflammation) and pain in the eye after a certain type of eye surgery (cataract surgery). Bromfenac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking the effects of certain natural substances (prostaglandins) that cause pain and inflammation.
Generic name: bromfenac sodium
Pronunciation: (BROME-fen-ak)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Bromday Twinpack
Indications
The following indications are listed for Bromday Twinpack:
- Post-Op Ocular Inflammation
- Postoperative Ocular Pain
Also known as: Post-Op Ocular Pain, Postoperative Eye Pain, Postoperative Ocular Inflammation, Postoperative Ophthalmic Inflammation.
Dosing
Dosage of bromfenac sodium, which is commercially available as the sesquihydrate, is expressed in terms of bromfenac.
The recommended adult dosage of bromfenac for the management of postoperative ocular inflammation and pain in patients who have undergone cataract extraction is 1 drop of a 0.09% solution in the affected eye(s) twice daily, beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.
Bromfenac sodium is applied topically to the eye as an ophthalmic solution. Care should be taken to avoid contamination of the solution container.
Bromfenac sodium ophthalmic solution should not be administered while wearing contact lenses.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies have been performed to date.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to bromfenac sodium or any ingredient in the formulation.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects reported in 2% or more of patients receiving bromfenac sodium ophthalmic solution include abnormal ocular sensation, conjunctival hyperemia, ocular redness or irritation (e.g., pruritus, burning, stinging, pain), headache, and iritis.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy not established in children younger than 18 years of age.
Category C. (See Users Guide.) Avoid use in late pregnancy (i.e., third trimester) because of known effects on fetal cardiovascular system (possible premature closure of the ductus arteriosus).
Not known whether bromfenac is distributed into milk following topical application to the eye. Caution if used in nursing women.
No substantial differences in safety and efficacy relative to younger adults.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.